Accéder au contenu
Merck

Screening and Characterization of Some Lactobacillaceae for Detection of Cholesterol-Lowering Activities.

Probiotics and antimicrobial proteins (2022-06-16)
Martin Frappier, Julie Auclair, Samir Bouasker, Sathursha Gunaratnam, Carine Diarra, Mathieu Millette
RÉSUMÉ

Dyslipidemia, specifically abnormal levels of low-density lipoprotein cholesterol (LDL-C), is an important risk factor of cardiovascular disease. Evidence showing the promising abilities of probiotics to lower total cholesterol or LDL-C has, however, not yet convinced experts to recommend probiotic bacteria as treatment for blood lipid management. Therefore, there are opportunities for the development of new efficient cholesterol-lowering probiotics. Bile salt hydrolase (BSH) and feruloyl esterase (FAE) are bacterial enzymes proposed to explain the cholesterol-lowering capacity of some bacteria and have both been shown to be responsible for lipid reduction in vivo. Here, in order to select for cholesterol-lowering bacteria, 70 strains related to Lactobacillaceae were screened for BSH and FAE activities. Based on this two-way screening approach, two bacteria were selected and assessed for their capacity to assimilate cholesterol in vitro, another suggested mechanism. Lactobacillus acidophilus CL1285 showed BSH and FAE activity as well as capacity to assimilate cholesterol in vitro. Lactiplantibacillus plantarum CHOL-200 exhibited BSH activity and ability to assimilate cholesterol. These properties observed in vitro make both strains good probiotic candidates for the management of dyslipidemia. Further investigation is needed to assess their ability to reduce blood cholesterol in human trial.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Pepsine from porcine gastric mucosa, powder, ≥250 units/mg solid
Sigma-Aldrich
Albumine de sérum bovin solution, 20 mg/mL in H2O, low bioburden, protease free, for molecular biology